Ruxolitinib improves the inflammatory microenvironment, restores glutamate homeostasis, and promotes functional recovery after spinal cord injury

Spinal cord injuries can cause loss of function below the injury site due to initial trauma and subsequent inflammation. Ruxolitinib, a drug that inhibits certain enzymes, can reduce inflammation and restore balance in the spinal cord, leading to improved motor function. The drug achieves this by helping astrocytes, which are brain cells, to remove excess glutamate, a substance that can damage neurons when present in high amounts.

• 1
  Ruxolitinib promotes motor function recovery and neuronal survival after spinal cord injury in mice.
• 2
  Ruxolitinib reverses the downregulation of EAAT2 after SCI, restoring glutamate homeostasis and reducing excitotoxicity.
• 3
  Ruxolitinib mitigates the activation of neurotoxic astrocytes and inflammatory responses following SCI in vivo and in vitro.